1246654-75-0

Basic information

• Product Name: 1-cyclopropyl-6-fluoro-8-Methoxy-4-oxo-7-(tetrahydro-1H-pyrrolo[3,4-b]pyridin-6(2H,7H,7aH)-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
• Synonyms: 1-cyclopropyl-6-fluoro-8-Methoxy-4-oxo-7-(tetrahydro-1H-pyrrolo[3,4-b]pyridin-6(2H,7H,7aH)-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
• CAS NO: 1246654-75-0
• Molecular Formula: C21H29ClFN3O4
• Molecular Weight: 441.9240632
• Mol File: 1246654-75-0.mol
• Article Data: 36

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-cyclopropyl-6-fluoro-8-Methoxy-4-oxo-7-(tetrahydro-1H-pyrrolo[3,4-b]pyridin-6(2H,7H,7aH)-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopropyl-6-fluoro-8-Methoxy-4-oxo-7-(tetrahydro-1H-pyrrolo[3,4-b]pyridin-6(2H,7H,7aH)-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride(1246654-75-0)
• EPA Substance Registry System: 1-cyclopropyl-6-fluoro-8-Methoxy-4-oxo-7-(tetrahydro-1H-pyrrolo[3,4-b]pyridin-6(2H,7H,7aH)-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride(1246654-75-0)

Safety Data

• Hazardous Substances Data: 1246654-75-0(Hazardous Substances Data)

Usage

Antibacterial Properties

This compound has potent antibacterial properties, making it effective in treating a wide range of bacterial infections.

Fluoroquinolone Antibiotics

It belongs to the class of fluoroquinolone antibiotics, which are a group of synthetic antimicrobial agents.

DNA Replication and Repair Inhibition

The compound works by inhibiting enzymes responsible for DNA replication and repair in bacteria, leading to bacterial death.

Broad-Spectrum Bacteria

It is effective against a broad spectrum of bacteria, including both Gram-positive and Gram-negative strains.

Specific Chemical Structure

The compound's specific chemical structure contributes to its effectiveness against various bacteria.

Hydrochloride Salt

The addition of hydrochloride salt to the compound enhances its solubility and bioavailability, making it easier to administer in medical settings.

Upstream product

• 151096-09-2 moxifloxacin 
• 151213-42-2 [R,R]-2,8-diazabicyclo[4.3.0]nonane 
• 139693-52-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid-O³,O⁴(bis(acyloxy-O)) borate 
• 151213-40-0 (1S,6S)-2,8-diazabicyclo[4.3.0]nonane 
• 139678-43-6 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (O₃,O⁴)bis(acyloxy-O)borate 
• 112811-71-9 ethyl 8-methoxy-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate 
• 1403836-23-6 ethyl 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 1082245-30-4 moxifloxacin tartaric acid 
• 128740-14-7 8-benzyl-2,8-diazabicyclo[4.3.0]nonane 
• 112811-70-8 ethyl 3-(cyclopropylamino)-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate 
• 151213-39-7 (S,S)-8-benzyl-2,8-diazabicyclo[4.3.0]nonane-D-tartrate 
• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 109-88-6 magnesium methanolate 

Relevant articles and documents

Preparation method of quinolone carboxylic acid derivative or phthalazinone carboxylic acid derivative

The invention belongs to the field of pharmaceutical chemicals, relates to a preparation method of a quinolone carboxylic acid derivative or a phthalazinone carboxylic acid derivative, and particularly relates to a preparation method of a 7-substituted-3-quinolone carboxylic acid derivative or a 7-substituted-1,5-phthalazinone carboxylic acid derivative. The preparation method comprises the following steps: (1) in an organic solvent, carrying out coupling reaction on a boron chelate II and organic amine III in the presence of an organosilicon compound to obtain a compound IV; and (2) mixing the compound IV with hydrochloric acid, and then filtering and separating the precipitated compound I. Compared with conventional methods, the preparation method provided by the invention has the advantages that the conditions are milder, the hydrolysis of the substrate quinoline carboxylic acid boric acid ester can be reduced, and meanwhile, the influence of a byproduct HF on the product purity is avoided. The method is high in yield and high in purity; compared with the traditional alkali, the organic silicon is more suitable for industrial preparation of the 7-substituted-3-quinolone carboxylic acid derivative or the 7-substituted-1,5-phthalazinone carboxylic acid derivative.

Preparation method of moxifloxacin hydrochloride (by machine translation)

The reaction: the reaction, is added into the reaction kettle, to heat, and then the,dihydro - 8 8-oxo- 3 3-dihydro-8-methoxy - 4 4-dioxanone introduced into the reaction kettle, is added to the reaction still 1 - for heating and reacting the, by the reaction; first and then, refluxing under, heating. 1st. The method comprises, condensation reaction; adding a protecting gas, to a reaction kettle.] and reacting, to obtain moxifloxacin hydrochloride; second by heating and reacting with a heating reaction of, by a heating reaction of a heating reaction unit of a reaction scheme of, second in a reaction still further, heating a reaction, solution in, a reaction still further to react with a, reaction gas, second and refluxing, the reaction. (S,S) - 2,8 - The method comprises the following steps of heating and separating [4.3 .0] out of a reaction; and refluxing the reaction gas . The reaction mixture; is introduced, into the reaction kettle. (by machine translation)

Synthetic method of moxifloxacin hydrochloride

The invention discloses a synthetic method of moxifloxacin hydrochloride. The synthetic method comprises the following steps: under the protection of argon, taking gatifloxacin carboxylate and (S,S)-2,8-diazabicyclo[4.3.0]nonane as raw materials; taking an organic alkali or an inorganic alkali as an acid-binding agent and a Lewis acid as a catalyst; reacting in a certain solvent at a proper temperature; concentrating, processing by alkali liquor, separating out moxifloxacin monomers at an isoelectric point, reacting moxifloxacin monomers with an acid to form salt, concentrating to obtain a moxifloxacin hydrochloride crude product, re-crystallizing, filtering, washing and drying to obtain a refined moxifloxacin hydrochloride finished product. The preparation method is mild in reaction conditions, simple to operate, less in pollution, and high in yield and industrial production can be realized easily.